Silicon Valley, September 7, 2018 –Mitre Medical has been invited to introduce the Mitral Touch epicardial annuloplasty system that enables a beating heart option for the surgical treatment of mitral regurgitation during the 9 September Innovator’s Day poster session, as part of the PCR London Valves meeting, to be held 9–11 September in London, UK.
Prof. Dr. med. Klaus Kallenbach of HaerzZenter Luxembourg will present the Mitre Medical epicardial annuloplasty approach during the EACTS Techno College session at the European Association for Cardio-Thoracic Surgery (EACTS) annual meeting on Thursday the 18th. His presentation, titled “Epicardial annuloplasty: Introducing a beating heart option for surgical FMR repair,” will occur at 12:15 pm during the New Technology Meets Common Practice session. Prof. Kallenbach will also present 6 month follow-up results from the ENRAPT MR Trial for Epicardial Annuloplasty Repair on Saturday the 20th of October.
“The Mitre system is a promising minimally invasive surgical treatment solution for patients with mitral regurgitation. I look forward to sharing the clinical experience with my colleagues during the EACTS Congress in October,” commented Prof. Kallenbach.
About PCR-London Valves
PCR London Valves is an official course of the European Association of Percutaneous Cardiovascular Interventions. It is recognized as the world’s largest educational meeting approaching the question of patient care in the area of valvular heart disease. It specifically addresses percutaneous valve interventions and the rapidly expanding and innovative field of transcatheter therapies for valvular heart disease.
The European Association for Cardio-Thoracic Surgery was founded in 1986 as a European organization devoted to the practice of cardio-thoracic surgery. EACTS global membership 4000 includes surgeons, perfusionists and allied health professionals.
About Mitre Medical Corp.
Mitre Medical Corp. is a medical device company with headquarters in Silicon Valley. The focus of the company is the development of innovative solutions to treat structural heart disease, including the Mitral Touch® device. The Mitral Touch device is currently not approved by the FDA and is not CE marked.
Mitre Medical Corp.
John MacMahon, CEO